GRI Bio Launches Equity Offering to Fund IPF Drug Development

Ticker: GRI · Form: S-1 · Filed: Dec 8, 2025 · CIK: 1824293

Sentiment: bearish

Topics: Biotechnology, S-1 Filing, Public Offering, Warrants, Dilution Risk, IPF Treatment, Clinical Stage

Related Tickers: GRI

TL;DR

**GRI Bio's warrant-heavy offering with no minimum raise is a high-risk bet on a clinical-stage drug, signaling potential dilution and funding uncertainty for investors.**

AI Summary

GRI Bio, Inc. (GRI) is undertaking a public offering of up to 5,128,205 shares of common stock and accompanying Series F warrants, with an assumed combined public offering price of $1.95 per share and warrant, based on the December 2, 2025 Nasdaq closing price. The company is also offering up to 5,128,205 pre-funded warrants at an assumed combined price of $1.9499, alongside Series F warrants, primarily for purchasers exceeding 4.99% beneficial ownership. This offering, which has no minimum proceeds requirement, aims to fund the development of its lead product candidate, GRI-0621, an oral inhibitor of type 1 iNKT cells. GRI-0621 is being developed for severe fibrotic lung diseases like Idiopathic Pulmonary Fibrosis (IPF), a market affecting approximately 140,000 people in the U.S. and 3 million globally. Preliminary Phase 2a trial data for GRI-0621 in IPF patients indicated it was well-tolerated and inhibited iNKT cell activity, with 19 patients completing the treatment arm and 9 in the placebo arm. The company previously executed a one-for-17 reverse stock split on February 21, 2025, to adjust its share structure.

Why It Matters

This S-1 filing is critical for GRI Bio as it seeks to raise capital to advance GRI-0621, its lead drug candidate for Idiopathic Pulmonary Fibrosis (IPF), a severe and widespread fibrotic lung disease. For investors, the offering's structure, including warrants and no minimum raise, introduces significant dilution risk and uncertainty regarding the company's ability to achieve its business objectives. Employees and customers could see long-term benefits if GRI-0621 successfully progresses through clinical trials and addresses the unmet medical needs in IPF, where existing therapies have limited efficacy and significant side effects. In the competitive biopharmaceutical landscape, successful development of GRI-0621 could position GRI Bio as a key player in the treatment of inflammatory and fibrotic disorders, potentially disrupting the current market dominated by therapies with poor adherence.

Risk Assessment

Risk Level: high — The offering has 'no minimum number of securities or amount of proceeds required as a condition to closing,' meaning investors could commit capital without the company raising sufficient funds to achieve its business goals. Furthermore, the offering includes up to 5,128,205 shares of common stock and 5,128,205 Series F Warrants, plus up to 358,974 Placement Agent Warrants, indicating significant potential for future dilution for existing shareholders.

Analyst Insight

Investors should exercise extreme caution due to the high-risk nature of this offering, particularly the lack of a minimum raise and the substantial potential for dilution from the various warrants. Consider waiting for more definitive financial results or clearer funding commitments before investing, as the company's ability to execute its business plan is uncertain.

Key Numbers

Key Players & Entities

FAQ

What is GRI Bio, Inc. offering in its S-1 filing?

GRI Bio, Inc. is offering up to 5,128,205 shares of common stock and accompanying Series F warrants, or up to 5,128,205 pre-funded warrants and accompanying Series F warrants. The assumed combined public offering price for common stock and warrants is $1.95, while for pre-funded warrants and warrants it is $1.9499.

What is GRI-0621 and what disease is GRI Bio developing it for?

GRI-0621 is GRI Bio's lead product candidate, an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. The company is developing GRI-0621 for the treatment of severe fibrotic lung diseases, specifically Idiopathic Pulmonary Fibrosis (IPF), which affects approximately 140,000 people in the United States.

What are the key risks associated with GRI Bio's offering?

A primary risk is that there is no minimum amount of proceeds required for the offering to close, meaning GRI Bio may not raise sufficient funds to achieve its business objectives. Additionally, the issuance of up to 5,128,205 Series F Warrants and 358,974 Placement Agent Warrants presents significant potential for future dilution for existing shareholders.

What was the last reported sale price of GRI Bio's Common Stock on Nasdaq?

On December 2, 2025, the last reported sale price of GRI Bio's Common Stock on The Nasdaq Capital Market was $1.95 per share. This price is used as the assumed combined public offering price for the common stock and accompanying Series F Warrants.

Who is the placement agent for GRI Bio's offering and what are their fees?

H.C. Wainwright & Co., LLC is the exclusive placement agent for GRI Bio's offering. They will receive a cash fee equal to 7.0% of the aggregate gross proceeds, a management fee of 1.0% of gross proceeds, and reimbursement for non-accountable expenses of $25,000, legal fees up to $100,000, and clearing expenses up to $15,950. They will also receive Placement Agent Warrants to purchase 7.0% of the offered shares.

What was the impact of the February 2025 Reverse Stock Split on GRI Bio?

On February 21, 2025, GRI Bio effected a reverse stock split of its Common Stock at a ratio of one-for-17. This adjustment means all financial information, share numbers, option numbers, warrant numbers, and exercise prices in the prospectus have been restated to reflect this split.

What is the exercise price and expiration of the Series F Warrants in GRI Bio's offering?

Each Series F Warrant will have an exercise price of $1.95 per share. They will be exercisable beginning on the effective date of stockholder approval or upon issuance if Pricing Conditions are met, and will expire on the five-year anniversary of the Initial Issuance Date or the effective date of the Warrant Stockholder Approval.

What is the purpose of the Pre-Funded Warrants in GRI Bio's offering?

Pre-Funded Warrants are offered to purchasers whose acquisition of common stock would result in beneficial ownership exceeding 4.99% (or 9.99% at purchaser's election) of GRI Bio's outstanding Common Stock. This mechanism allows investors to limit their immediate beneficial ownership while still participating in the offering.

What are the preliminary findings from GRI Bio's Phase 2a trial for GRI-0621 in IPF?

Preliminary and topline data from the Phase 2a trial for GRI-0621 in IPF patients indicated that the drug was well-tolerated and inhibited iNKT cell activity in subjects. The trial enrolled 35 patients, with 19 completing treatment in the GRI-0621 arm and 9 in the placebo arm.

Is there a public trading market for the Series F Warrants or Pre-Funded Warrants of GRI Bio?

No, there is no established public trading market for the Series F Warrants or the Pre-Funded Warrants, and GRI Bio does not expect a market to develop. The company does not intend to apply for listing of these warrants on any securities exchange, which will limit their liquidity.

Filing Stats: 4,723 words · 19 min read · ~16 pages · Grade level 15 · Accepted 2025-12-08 08:19:41

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 10 Cautionary Note Regarding Forward-Looking Statements 52

Use of Proceeds

Use of Proceeds 54 Market Information 55 Dividend Policy 56 Capitalization 57

Dilution

Dilution 58 Management's Discussion a nd Analysis of Financial Condition and Results of Operations 60

Business

Business 68 Management 109 Executive And Director Compensation 116 Certain Relationships a nd Related Party Transactions 122

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management 124

Description of Capital Stock

Description of Capital Stock 126

Description of Securities We Are Offering

Description of Securities We Are Offering 131 Material U.S. Federal Income Tax Consequences to Holders of Common Stock, Pre-Funded Warrants and Series F Warrants 135 Plan of Distribution 142 Legal Matters 146 Experts 146 Change in Auditor 146 Where You Can Find More Information 146 Index to Consolidated Financial Statements F- 1 You should rely only on the information contained in this prospectus. No one, including but not limited to the Placement Agent, has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. i ABOUT THIS PROSPECTUS Unless the context otherwise requires or as otherwise noted, we use the terms "GRI," "Company," "we," "us" and "our" in this prospectus to refer to GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc. (Vallon)) and its subsidiaries taken as a whole. We have not, and the Placement Agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information provided in this prospectus contains statistical data and estimates, inc

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing